About
About the 3rd Liquid Biopsy Surveillance Summit
The 3rd Liquid Biopsy Surveillance Summit is at the forefront of innovation in cancer care, with a focus on advancing the monitoring of patients through cutting-edge minimal residual disease (MRD) detection. This industry-defining event delves into the latest developments in ctDNA analysis, offering new capabilities for continuous and precise patient surveillance. By enhancing real-time monitoring, these advancements are setting new standards in oncology, enabling more effective disease management and improved patient outcomes.
Join leading experts and industry pioneers as we explore the future of MRD-driven surveillance and its transformative impact on personalized cancer care.
Join Your Peers to:
Connect with the key decision-makers driving innovation in the liquid biopsy field – engage with leaders from AstraZeneca, Amgen, AbbVie, Bristol Myers Squibb, GSK, Takeda, and more, all dedicated to advancing the future of liquid biopsy technology
Establish relationships with the trailblazing biotech companies leading the charge in enhancing patient surveillance. Join forward-thinking innovators like Compass Therapeutics, Foghorn Therapeutics, Repare Therapeutics, Synnovation Therapeutics, and others as they pave the way for the future of patient care
Engage in dynamic 3+ panel discussions that foster open dialogue on MRD detection, endpoint development, patient selection, and dosage regimens
Network with leading diagnostic partners such as Personalis, Foundation Medicine, Burning Rock Biotech, and others, as they unveil ground-breaking technological advancements poised to revolutionize your clinical trials
Who Will You Meet?
At the Liquid Biopsy Surveillance Summit, you’ll have the opportunity to connect with a highly influential and diverse group of professionals at the forefront of cancer care innovation. Expect to engage with senior leaders, including C-level executives, vice presidents, directors, and heads who are driving strategic decisions in drug development, precision medicine, and patient surveillance.
Previous Attendees Have Included:
What Your Peers Have to Say
“Liquid Biopsies are transforming detection and treatment of many cancers. I look forward to sharing our experiences in MRD in hematologic conditions.”
Speaker, Director - Translational Science, Cancer, Foundation for the NIH
“I have found the meetings to be invaluable for networking with drug development colleagues and diagnostic partners. I always learn something new, and these meetings have significantly influenced the biomarker strategies I have implemented”
Speaker, Associate Director Translational Medicine
Repare Therapeutics
“The event offered a great opportunity to network and promote my company and its services to advance the study in cancer treatment”
Previous Event Partner, Translational Medicine Scientist, Burning Rock Biotech
“It was a great meeting. The topics presented were UpToDate with some information were new. Glad that equity, diversity and inclusion was one of the topics for panel discussion.”
Past Attendee, Associate Director – Precision Medicine, Takeda
“I really enjoyed the mix of speakers and topics - it was nice to see a variety of LBx applications (ctDNA, exosomes, CTCs) and hear from both industry and institutions.”
Past Attendee, Director, AstraZeneca
